Cannabis Benefits and Risks: What a Meta-Analysis Found
A psychiatry review found that cannabinoids showed only modest benefits for nausea and small or inconsistent benefits for pain and spasticity, while risks included cognitive impairment, traffic accidents, dependence, and psychosis.
Quick Facts
What This Study Found
This review summarized the evidence on both benefits and risks of cannabis and cannabinoids. On the benefit side, a recent meta-analysis found cannabinoids were associated with modest benefits for chemotherapy-related nausea, small and inconsistent benefits for pain and spasticity, and inconclusive benefits for appetite, tics, mood, and sleep.
On the risk side, randomized controlled trials showed cannabinoids increase the risk of adverse events, serious adverse events, and dropout due to adverse events. Cannabis impairs cognition and is associated with increased traffic accident risk including fatal crashes. Long-term use may lead to dependence, respiratory problems, psychosis, and possibly cancer.
The review also noted concerns about use during pregnancy (potentially compromising fetal growth) and adolescence (potentially affecting neurodevelopment and social adjustment), and cautioned that older research findings may not apply to current high-potency strains.
Key Numbers
No new quantitative data presented. The review cited meta-analytic evidence of modest benefits for nausea, small/inconsistent benefits for pain and spasticity, and increased odds of adverse events, traffic accidents, dependence, and psychosis.
How They Did This
This was a clinical review published in the Journal of Clinical Psychiatry, synthesizing evidence from meta-analyses, randomized controlled trials, and observational studies on both the therapeutic benefits and health risks of cannabis.
Why This Research Matters
This review provides a balanced assessment at a time when public perception often skews toward viewing cannabis as either completely benign or as a cure-all. The modest therapeutic benefits need to be weighed against documented risks, particularly for vulnerable populations.
The Bigger Picture
The gap between public perception of cannabis safety and the documented risk profile highlighted in this review remains relevant. As cannabis potency has continued to increase since 2016, some of the risk concerns, particularly around psychosis and dependence, have become more pressing.
What This Study Doesn't Tell Us
This was a narrative review that selectively summarized existing evidence. It did not conduct a systematic search or meta-analysis. The balance of benefit-to-risk reporting reflects the author's perspective. Cannabis research has continued to evolve since publication.
Questions This Raises
- ?How do the risks and benefits of cannabis compare to commonly prescribed alternatives for the same conditions?
- ?Are the risks proportional to dose, frequency, and potency of cannabis used?
Trust & Context
- Key Stat:
- Benefits: modest for nausea, small for pain. Risks: cognitive impairment, accidents, dependence, psychosis.
- Evidence Grade:
- This is a clinical review synthesizing meta-analyses and trial data, providing a moderate-quality evidence overview.
- Study Age:
- Published in 2016. The evidence base for both benefits and risks of cannabis has continued to grow.
- Original Title:
- Cannabis and neuropsychiatry, 1: benefits and risks.
- Published In:
- The Journal of clinical psychiatry, 77(5), e551-4 (2016)
- Authors:
- Andrade, Chittaranjan(4)
- Database ID:
- RTHC-01093
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is cannabis an effective medicine?
The evidence cited in this review suggests modest effectiveness for specific conditions (chemotherapy nausea) and small or inconsistent effects for others (pain, spasticity). The therapeutic window appears narrower than popular perception suggests.
What are the most serious risks of cannabis use?
The review highlighted cognitive impairment, increased traffic accident risk, dependence (affecting about 9% of users overall and higher among those who start young), psychosis risk, and potential respiratory and pregnancy-related harms.
Read More on RethinkTHC
- LGBTQ-cannabis-use-recovery-support
- cannabis-induced-psychosis
- online-therapy-cannabis-anxiety-review
- quitting-weed-adhd
- quitting-weed-depression
- quitting-weed-ptsd
- self-medicating-with-weed
- weed-OCD-intrusive-thoughts
- weed-and-ptsd
- weed-childhood-trauma-ACE
- weed-suicidal-thoughts-withdrawal
- thc-and-coordination-balance-motor-skills
Cite This Study
https://rethinkthc.com/research/RTHC-01093APA
Andrade, Chittaranjan. (2016). Cannabis and neuropsychiatry, 1: benefits and risks.. The Journal of clinical psychiatry, 77(5), e551-4. https://doi.org/10.4088/JCP.16f10841
MLA
Andrade, Chittaranjan. "Cannabis and neuropsychiatry, 1: benefits and risks.." The Journal of clinical psychiatry, 2016. https://doi.org/10.4088/JCP.16f10841
RethinkTHC
RethinkTHC Research Database. "Cannabis and neuropsychiatry, 1: benefits and risks." RTHC-01093. Retrieved from https://rethinkthc.com/research/andrade-2016-cannabis-and-neuropsychiatry-1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.